- Research article
- Open Access
Staphylococcus aureus small colony variants are susceptible to light activated antimicrobial agents
BMC Microbiologyvolume 13, Article number: 201 (2013)
Antibiotic therapy can select for small colony variants of Staphylococcus aureus that are more resistant to antibiotics and can result in persistent infections, necessitating the development of more effective antimicrobial strategies to combat small colony variant infections. Photodynamic therapy is an alternative treatment approach which utilises light in combination with a light-activated antimicrobial agent to kill bacteria via a non-specific mechanism of action. In this study, we investigated whether the combination of 665 nm laser light and the light-activated antimicrobial agent methylene blue was able to successfully kill S. aureus small colony variants. S. aureus and isogenic stable small colony variant were exposed to varying doses (1.93 to 9.65 J/cm2) of 665 nm laser light in the presence of varying concentrations (1 to 20 μM) of methylene blue.
The combination of 665 nm laser light and methylene blue was found to be an effective strategy for the killing of small colony variants. At the highest light dose (9.65 J/cm2) and methylene blue concentration (20 μM) tested, the number of viable bacteria decreased by approximately 6.9 log10 for the wild type and approximately 5 log10 for the small colony variant.
These results suggest that photodynamic therapy has potential for use in the treatment of superficial infections caused by small colony variants of S. aureus and supports further research in this field.
Small colony variants (SCVs) of Staphylococcus aureus are a naturally-occurring subpopulation often associated with chronic antibiotic exposure . S. aureus SCVs are characterized by their slow growth rate and small colony size relative to the parent strain, and can cause persistent infections in the lungs of cystic fibrosis patients and infections of skin, bone and implanted devices .
S. aureus SCVs are clinically important due to their reduced susceptibility to antibiotics. SCVs are commonly auxotrophs for hemin, menadione or thymidine, resulting in electron transport chain defects and consequently reduced membrane potential and reduced uptake of cationic antibiotics . Resistance to cell wall–active antibiotics such as β-lactams occurs due to the slow growth rate and reduced cell wall metabolism of SCVs .
Given their persistent nature and their selection by and resistance to conventional antibiotics, there is a need to identify effective therapies for SCV infections. One potential novel strategy is photodynamic therapy, which utilizes light in combination with a light-activated antimicrobial agent, known as a photosensitiser, to generate toxic reactive oxygen species such as free radicals and singlet oxygen. Upon irradiation, the photosensitiser undergoes a transition from a low energy ground state to a higher energy triplet state, which can then react with biomolecules to produce free radicals or with molecular oxygen to produce highly reactive singlet oxygen. These reactive oxygen species can oxidise many biological structures and kill bacteria via several mechanisms, most notably by damaging the cytoplasmic membrane .
There are several potential advantages of light-activated antimicrobial agents over conventional antimicrobial therapy. Firstly, collateral damage to the host or host microbiota is limited due to the very short half-life and diffusion distance of the reactive oxygen species produced. Secondly, resistance is unlikely as reactive oxygen species kill bacteria through non-specific mechanisms, by attacking proteins, lipids and nucleic acids. We have previously shown that light-activated antimicrobial agents such as methylene blue and tin (IV) chlorin e6 are effective against meticillin-sensitive S. aureus, epidemic meticillin-resistant S. aureus (MRSA), community-acquired MRSA and vancomycin intermediate S. aureus (VISA) [6, 7], and are effective for decolonizing wound infections in vivo. However given that most light activated antimicrobials are cationic compounds and that SCVs have a reduced membrane potential which makes them more resistant to cationic antimicrobials it is possible that such light activated antimicrobials would not be effective at killing SCVs. Therefore the aim of this study was to determine the capacity of the cationic light activated antimicrobial agent methylene blue in combination with 665 nm laser light to kill S. aureus SCVs.
Results and discussion
As mentioned small colony variants of S. aureus have been reported to have increased resistance to conventional antimicrobials such as aminoglycosides. In this study we determined that the minimum inhibitory concentration of the aminoglycoside kanamycin against the hemB and menD small colony variants was 8-fold higher (128 μg/ml) than the isogenic parent strains (16 μg/ml).
The hemB SCV and its isogenic parent were both found to be susceptible to photodynamic killing using methylene blue and 1.93 J/cm2 of 665 nm laser light in a methylene blue concentration-dependent manner (Figure 1). Neither laser light nor photosensitiser alone had any effect on bacterial viability (data not shown). The menD SCV and its wild-type parent were also susceptible to photodynamic killing by methylene blue (20 μM) and 1.93 J/cm2 of 665 nm laser light, with reductions in cell viability of 3.5 log10 and 4.1 log10, respectively (data not shown). Increasing the light dose was found to significantly increase the killing of both the hemB SCV and its parent strain; the highest light dose examined (9.65 J/cm2) resulted in reductions in viable cells of approximately 6.9 log10 and 5 log10 respectively (Figure 2). There was no significant difference between the kills observed for both strains when a light dose of 9.65 J/cm2 was used for the experiments.
Small colony variants of S. aureus represent a serious challenge to clinicians treating infections caused by these microorganisms  due to the increased antibiotic resistance and persistent infections that are characteristic of SCVs [1, 3, 4]. It would therefore be advantageous to develop a therapeutic strategy with a differing mode of action to those antibiotics for which lower susceptibility is observed. We have previously shown that light-activated antimicrobial agents, which have a non-specific mode of action, are highly effective at killing S. aureus[6–8]. To investigate the capacity of the light-activated antimicrobial agent methylene blue in combination with laser light for eradicating SCVs of S. aureus, we used stable hemin (hemB mutant) and menadione (menD mutant) auxotrophic SCVs of S. aureus, which we found to have an 8-fold increase in resistance to the aminoglycoside kanamycin. Our results demonstrate that the combination of methylene blue and laser light of 665 nm effectively kills S. aureus SCVs, suggesting that photodynamic therapy could be a promising alternative therapy for SCV infections. Selection for SCVs and development of resistance are unlikely due to the non-specific mechanism of action of photodynamic therapy, representing an advantage over conventional antibiotic treatment. One potential limitation to the effectiveness of photodynamic therapy is that in some infections SCVs enter the cytoplasm of host cells . In such cases it is likely that higher photodynamic therapy doses would be required resulting in some collateral damage to host tissue. One possible way to overcome this problem would be to develop photosensitisers that target the intracellular bacteria specifically.
Photodynamic therapy has been proposed for the decontamination of the anterior nares in cases of MRSA carriage [6, 8, 9]. Cases of infections associated with concomitant colonisation of the anterior nares by S. aureus small colony variants have been reported in the literature [10–12]; therefore, photodynamic therapy may also be of use as a decontamination strategy in cases where the anterior nares represent a reservoir of SCVs.
In conclusion, we propose that photodynamic therapy has potential for use in the treatment of superficial infections by SCVs of S. aureus and for nasal decolonisation.
The S. aureus strains used were the laboratory strain 8325–4 and an isogenic mutant, D1324, disrupted in menD, (a gift from Professor Richard Proctor), and LS-1 and its isogenic mutant disrupted in hemB. S. aureus was maintained by subculture on blood agar (Oxoid Ltd, UK) incubated aerobically at 37°C. For experimental purposes, bacteria were inoculated into Brain Heart Infusion broth and cultured aerobically for 16 hrs at 37°C, with shaking at 200 rpm. Cultures were then centrifuged and resuspended in an equal volume of PBS and the optical density adjusted to 0.05 at 600 nm, corresponding to approximately 1 × 107 colony forming units (CFU) per mL. Methylene blue (C16H18ClN3S.3H2O) and all other reagents were purchased from Sigma-Aldrich (UK).
The MIC of kanamycin was determined according to the CLSI microbroth dilution. A Periowave™ diode laser (Ondine Biomedical Inc., Canada), which emits light with a wavelength of 665 nm was used throughout the study. The power output of the laser was 73 mW and the beam diameter was 1.7 cm. The laser system was set up so that the laser beam covered the entire well of a microtitre plate in which experiments were performed. To examine the effect of photosensitiser concentration on the photodynamic killing of S. aureus SCVs, methylene blue was diluted in PBS to give final concentrations of 1, 5, 10 and 20 μM. Methylene blue (50 μL) was added to an equal volume of the inoculum in triplicate wells of a sterile, flat-bottomed 96-well plate and irradiated with 665 nm laser light with an energy density of 1.93 J/cm2, with stirring. Three additional wells containing 50 μL of methylene blue and 50 μL of the bacterial suspension were kept in the dark to assess the toxicity of the photosensitiser alone. To assess the toxicity of laser light alone, 50 μL PBS was added to 50 μL of the inoculum in a further six wells, three of which were irradiated with laser light and the remaining three kept in the dark. Following irradiation/dark incubation, samples were serially diluted 10-fold in PBS and plated onto 5% horse blood agar plates in triplicate. The plates were incubated aerobically overnight at 37°C, following which the surviving CFU/mL were enumerated by viable counting. Experiments were performed three times in triplicate.
To examine the effect of laser light dose on the photodynamic killing of the SCVs, methylene blue was diluted in PBS to give a final concentration of 20 μM. Experiments were performed as described above, but bacteria were irradiated with 1.93 J/cm2, 3.86 J/cm2 or 9.65 J/cm2 of 665 nm laser light, with stirring. Following irradiation/dark incubation, viable bacteria were enumerated as described as above.
von Eiff C, Peters G, Becker K: The small colony variant (SCV) concept – the role of staphylococcal SCVs in persistent infections. Injury. 2006, 37 (suppl 2): S26-S33.
von Eiff C: Staphylococcus aureus small colony variants: a challenge to microbiologists and clinicians. Int J Antimicrob Agents. 2008, 31: 507-510. 10.1016/j.ijantimicag.2007.10.026.
Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, et al: Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol. 2006, 4: 295-305. 10.1038/nrmicro1384.
Proctor RA, Kahl B, von Eiff C, Vaudaux PE, Lew DP, Peters G: Staphylococcal small colony variants have novel mechanisms for antibiotic resistance. Clin Infect Dis. 1998, 27 (suppl 1): S68-S74.
Hamblin MR, Hasan T: Photodynamic Therapy: A New Antimicrobial Approach to Infectious Disease?. Photochem Photobiol Sci. 2004, 3: 436-450. 10.1039/b311900a.
Embleton ML, Nair SP, Cookson BD, Wilson M: Selective lethal photosensitisation of methicillin-resistant Staphylococcus aureus using an IgG-tin (IV) chlorin e6 conjugate. J Antimicrob Chemother. 2002, 50 (6): 857-864. 10.1093/jac/dkf209.
Embleton ML, Nair SP, Heywood W, Menon DC, Cookson BD, Wilson M: Development of a novel targeting system for lethal photosensitisation of antibiotic-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother. 2005, 49 (9): 3690-3696. 10.1128/AAC.49.9.3690-3696.2005.
Zolfaghari PS, Packer S, Singer M, Nair SP, Bennett J, Street C, et al: In vivo killing of Staphylococcus aureus using a light-activated antimicrobial agent. BMC Microbiol. 2009, 9: 27-10.1186/1471-2180-9-27.
Street CN, Pedigo L, Gibbs A, Loebel NG: Antimicrobial photodynamic therapy for the decolonization of methicillin-resistant Staphylococcus aureus from the anterior nares. 12th World Congress of the International Photodynamic Association. International Society for Optics and Photonics. Edited by: David HK. 2009
Hale JH: Studies on Staphylococcus Mutation: A Naturally Occurring “G” Gonidial Variant and Its Carbon Dioxide Requirements. Br J Exp Pathol. 1951, 32: 307-313.
Proctor RA, Vanlangevelde P, Kristjansson M, Maslow JN, Arbeit RD: Persistent and Relapsing Infections Associated with Small-Colony Variants of Staphylococcus aureus. Clin Infect Dis. 1995, 20: 95-102. 10.1093/clinids/20.1.95.
von Eiff C, Becker K, Metze D, Lubritz G, Hockmann J, Schwarz T, et al: Intracellular Persistence of Staphylococcus aureus Small-Colony Variants within Keratinocytes: A Cause for Antibiotic Treatment Failure in a Patient with Darier’s Disease. Clin Infect Dis. 2001, 32: 1643-1647. 10.1086/320519.
Bates DM, von Eiff C, McNamara PJ, Peters G, Yeaman MR, Bayer AS, et al: Staphylococcus aureus menD and hemB mutants are as infective as the parent strains, but the menadione biosynthetic mutant persists within the kidney. J Infect Dis. 2003, 187 (10): 1654-1661. 10.1086/374642.
Wright JA, Nair SP: The lipoprotein components of the Isd and Hts transport systems are dispensable for acquisition of heme by Staphylococcus aureus. FEMS Microbiol Lett. 2012, 329 (2): 177-185. 10.1111/j.1574-6968.2012.02519.x.
John Wright and Sean Nair received funding from the charity Arthritis Research UK (grant number 18294). Ping Zhang received a studentship from the Eastman Foundation for Oral Research and Training (grant number 18294).
ST received a studentship stipend from Ondine Biopharma Inc. and MW holds shares in Ondine Biopharma Inc.
ST: participated in the study design, carried out the experimental work, performed the statistical analysis and drafted the manuscript. MW: conceived of the study, participated in its design and helped to draft the manuscript. JAW carried out the experimental work and helped draft the manuscript. PZ carried out the experimental work and helped draft the manuscript. SPN: conceived of the study, participated in its design, interpreted the data, and drafted the manuscript. All authors read and approved the final manuscript.